Le Lézard
Classified in: Health
Subject: SVY

The global Helicobacter pylori non-invasive testing market is expected to reach US$ 768.23 Mn in 2027 from US$ 539.70 Mn in 2018


NEW YORK, Sept. 18, 2019 /PRNewswire/ --

The global Helicobacter pylori non-invasive testing market is expected to reach US$ 768.23 Mn in 2027 from US$ 539.70 Mn in 2018. The Helicobacter pylori non-invasive testing market is estimated to grow with a CAGR of 4.1% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05815405/?utm_source=PRN

The market is driven by the factors such as, increasing prevalence of Helicobacter pylori bacterial infection, new product launches & FDA approvals, and spreading awareness by government for proper diagnosis. However, factor such as low diagnosis rate is the major restraining factors for the growth of the market.
Helicobacter pylori infection affects more than half of the world's population. The infection is generally acquired during childhood but can remain asymptomatic, with long-term clinical sequelae including gastritis, peptic ulcer disease, and stomach cancer.
According to MEDLINE and EMBASE databases and United Nations, in 2015, Africa had the highest pooled prevalence of Helicobacter pylori infection (70.1%), whereas Oceania had the lowest prevalence (24.4%). Among individual countries, In Switzerland, the prevalence of Helicobacter pylori infection varied from as low as 18.9% to 87.7% in Nigeria. Based on regional prevalence estimates, there were approximately 4.4 billion individuals with Helicobacter pylori infection worldwide in 2015.
Also, according to World health Organization (WHO), 90% high prevalence rate has been observed in developing countries, whereas in developed countries the prevalence rate is low, i.e. 50%. The global Helicobacter pylori infection rate in female was found to be 42.7% as compared to 46.3% in males. Moreover, in adult it was significantly higher as compared to children, 48.6% and 32.6% respectively.
These statistics determine an increase in the demand for diagnostics in various regions across the globe. Hence, driving the growth of the Helicobacter pylori Non-Invasive Testing Market during the forecast period.
Global Helicobacter pylori non-invasive testing market was segmented by test type, test method and end user.On the basis of the test the market is segmented as serology tests, stool antigen tests, and urea breath tests.

Based on the test method the market is segmented into laboratory based test and point of care test. And the market is classified into hospitals, clinics, and diagnostic laboratories on the basis of end user.
Some of the major primary and secondary sources included in the report for the Helicobacter pylori non-invasive testing market are Italian Association for Cancer Research, Cancer Association of South Africa, Canadian Institutes of Health Research, Food and Drug Administration, and others.

Read the full report: https://www.reportlinker.com/p05815405/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE ReportBuyer


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: